This finding is consistent with previous case reports and results of small studies, in which WT1 vaccine therapy produced clinical and immunological responses and improved clinical manifestations and quality of life in patients with glioblastoma and glioma28,47–50, warranting further investigation in this subgroup of patients. This evidence concerns the gene WT1 and glioblastoma.